Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer
Background: The purpose of this study was to compare quality of life and overall toxicity in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine–gemcitabine (VG) or carboplatin–paclitaxel (Taxol) (CP). Patients and methods: A total of 165 previously untreated patients...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2005-01, Vol.16 (1), p.97-101 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101 |
|---|---|
| container_issue | 1 |
| container_start_page | 97 |
| container_title | Annals of oncology |
| container_volume | 16 |
| creator | Lilenbaum, R. C. Chen, C.-S. Chidiac, T. Schwarzenberger, P. O. Thant, M. Versola, M. Lane, S. R. |
| description | Background: The purpose of this study was to compare quality of life and overall toxicity in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine–gemcitabine (VG) or carboplatin–paclitaxel (Taxol) (CP). Patients and methods: A total of 165 previously untreated patients were randomized to the two regimens. Quality of life was assessed by the Lung Cancer Symptom Scale (LCSS). Overall toxicity and secondary efficacy end points were evaluated by standard WHO criteria. Results: There was no significant difference in overall quality of life between the two treatments. Neutropenia, thrombocytopenia, peripheral neuropathy, and alopecia, were more common in the CP arm, whereas constipation was more frequent in the VG arm. Response rates were 14.6% in the VG arm and 16.9% in the CP arm. Median survival times were 7.8 and 8.6 months, and 1 year survival rates were 38.4% and 31.9%, respectively. Conclusions: Patients treated with VG experienced lower toxicity, but overall quality of life was similar in both arms. Efficacy seemed comparable between VG and CP. Our study shows that VG is a viable alternative to platinum-based chemotherapy in patients with advanced NSCLC. |
| doi_str_mv | 10.1093/annonc/mdi009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21296751</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21296751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-ee4cf51e86e0008cd678458902d40941c502d666c563583ee72b5ff4b8df63c23</originalsourceid><addsrcrecordid>eNpFkM1P3DAQxS1UBFvgyLXypdwCdvyR-FjRAishwQEQ4mI5zoQaHGdrJyvaG_95veyKPXns95s344fQMSWnlCh2ZkIYgj3rW0eI2kEzKqQqasLpFzQjqmRFJRjfR19TeiGESFWqPbRPhVC14mKG3m9_mwR4PsfRhHbo3T9o8Rid8Xjo8NKFIYJvXACcZfwMvXWj-bgvIaYpYWtiMyy8GV34QBbG-oy8gcerl3Zpgs2Wecki9cb7woL32E_hObdmKR6i3c74BEeb8wDdX_y6O78qrm8u5-c_rgvLSzUWANx2gkItIf-jtq2sai5qRcqWE8WpFbmSUlohmagZQFU2out4U7edZLZkB-hk7buIw58J0qh7l1bLmADDlHRJSyUrQTNYrEEbh5QidHoRXW_iX02JXmWu15nrdeaZ_7Yxnpoe2i29CTkD3zeASdb4LidtXdpyklPKhdgOdmmEt0_dxFctK1YJffX4pHl1KX8-EKUl-w-tFJyf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21296751</pqid></control><display><type>article</type><title>Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Lilenbaum, R. C. ; Chen, C.-S. ; Chidiac, T. ; Schwarzenberger, P. O. ; Thant, M. ; Versola, M. ; Lane, S. R.</creator><creatorcontrib>Lilenbaum, R. C. ; Chen, C.-S. ; Chidiac, T. ; Schwarzenberger, P. O. ; Thant, M. ; Versola, M. ; Lane, S. R.</creatorcontrib><description>Background: The purpose of this study was to compare quality of life and overall toxicity in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine–gemcitabine (VG) or carboplatin–paclitaxel (Taxol) (CP). Patients and methods: A total of 165 previously untreated patients were randomized to the two regimens. Quality of life was assessed by the Lung Cancer Symptom Scale (LCSS). Overall toxicity and secondary efficacy end points were evaluated by standard WHO criteria. Results: There was no significant difference in overall quality of life between the two treatments. Neutropenia, thrombocytopenia, peripheral neuropathy, and alopecia, were more common in the CP arm, whereas constipation was more frequent in the VG arm. Response rates were 14.6% in the VG arm and 16.9% in the CP arm. Median survival times were 7.8 and 8.6 months, and 1 year survival rates were 38.4% and 31.9%, respectively. Conclusions: Patients treated with VG experienced lower toxicity, but overall quality of life was similar in both arms. Efficacy seemed comparable between VG and CP. Our study shows that VG is a viable alternative to platinum-based chemotherapy in patients with advanced NSCLC.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdi009</identifier><identifier>PMID: 15598945</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject><![CDATA[Adult ; advanced non-small-cell lung cancer ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carboplatin - administration & dosage ; carboplatin–paclitaxel ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Female ; Humans ; Infusions, Intravenous ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Male ; Medical sciences ; Middle Aged ; Paclitaxel - administration & dosage ; Pharmacology. Drug treatments ; Pneumology ; Quality of Life ; Survival Analysis ; Treatment Outcome ; Tumors of the respiratory system and mediastinum ; Vinblastine - administration & dosage ; Vinblastine - analogs & derivatives ; Vinorelbine ; vinorelbine–gemcitabine]]></subject><ispartof>Annals of oncology, 2005-01, Vol.16 (1), p.97-101</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-ee4cf51e86e0008cd678458902d40941c502d666c563583ee72b5ff4b8df63c23</citedby><cites>FETCH-LOGICAL-c429t-ee4cf51e86e0008cd678458902d40941c502d666c563583ee72b5ff4b8df63c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16411455$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15598945$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lilenbaum, R. C.</creatorcontrib><creatorcontrib>Chen, C.-S.</creatorcontrib><creatorcontrib>Chidiac, T.</creatorcontrib><creatorcontrib>Schwarzenberger, P. O.</creatorcontrib><creatorcontrib>Thant, M.</creatorcontrib><creatorcontrib>Versola, M.</creatorcontrib><creatorcontrib>Lane, S. R.</creatorcontrib><title>Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: The purpose of this study was to compare quality of life and overall toxicity in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine–gemcitabine (VG) or carboplatin–paclitaxel (Taxol) (CP). Patients and methods: A total of 165 previously untreated patients were randomized to the two regimens. Quality of life was assessed by the Lung Cancer Symptom Scale (LCSS). Overall toxicity and secondary efficacy end points were evaluated by standard WHO criteria. Results: There was no significant difference in overall quality of life between the two treatments. Neutropenia, thrombocytopenia, peripheral neuropathy, and alopecia, were more common in the CP arm, whereas constipation was more frequent in the VG arm. Response rates were 14.6% in the VG arm and 16.9% in the CP arm. Median survival times were 7.8 and 8.6 months, and 1 year survival rates were 38.4% and 31.9%, respectively. Conclusions: Patients treated with VG experienced lower toxicity, but overall quality of life was similar in both arms. Efficacy seemed comparable between VG and CP. Our study shows that VG is a viable alternative to platinum-based chemotherapy in patients with advanced NSCLC.</description><subject>Adult</subject><subject>advanced non-small-cell lung cancer</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carboplatin - administration & dosage</subject><subject>carboplatin–paclitaxel</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Paclitaxel - administration & dosage</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Quality of Life</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - analogs & derivatives</subject><subject>Vinorelbine</subject><subject>vinorelbine–gemcitabine</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1P3DAQxS1UBFvgyLXypdwCdvyR-FjRAishwQEQ4mI5zoQaHGdrJyvaG_95veyKPXns95s344fQMSWnlCh2ZkIYgj3rW0eI2kEzKqQqasLpFzQjqmRFJRjfR19TeiGESFWqPbRPhVC14mKG3m9_mwR4PsfRhHbo3T9o8Rid8Xjo8NKFIYJvXACcZfwMvXWj-bgvIaYpYWtiMyy8GV34QBbG-oy8gcerl3Zpgs2Wecki9cb7woL32E_hObdmKR6i3c74BEeb8wDdX_y6O78qrm8u5-c_rgvLSzUWANx2gkItIf-jtq2sai5qRcqWE8WpFbmSUlohmagZQFU2out4U7edZLZkB-hk7buIw58J0qh7l1bLmADDlHRJSyUrQTNYrEEbh5QidHoRXW_iX02JXmWu15nrdeaZ_7Yxnpoe2i29CTkD3zeASdb4LidtXdpyklPKhdgOdmmEt0_dxFctK1YJffX4pHl1KX8-EKUl-w-tFJyf</recordid><startdate>200501</startdate><enddate>200501</enddate><creator>Lilenbaum, R. C.</creator><creator>Chen, C.-S.</creator><creator>Chidiac, T.</creator><creator>Schwarzenberger, P. O.</creator><creator>Thant, M.</creator><creator>Versola, M.</creator><creator>Lane, S. R.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>200501</creationdate><title>Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer</title><author>Lilenbaum, R. C. ; Chen, C.-S. ; Chidiac, T. ; Schwarzenberger, P. O. ; Thant, M. ; Versola, M. ; Lane, S. R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-ee4cf51e86e0008cd678458902d40941c502d666c563583ee72b5ff4b8df63c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>advanced non-small-cell lung cancer</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carboplatin - administration & dosage</topic><topic>carboplatin–paclitaxel</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Paclitaxel - administration & dosage</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Quality of Life</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - analogs & derivatives</topic><topic>Vinorelbine</topic><topic>vinorelbine–gemcitabine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lilenbaum, R. C.</creatorcontrib><creatorcontrib>Chen, C.-S.</creatorcontrib><creatorcontrib>Chidiac, T.</creatorcontrib><creatorcontrib>Schwarzenberger, P. O.</creatorcontrib><creatorcontrib>Thant, M.</creatorcontrib><creatorcontrib>Versola, M.</creatorcontrib><creatorcontrib>Lane, S. R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lilenbaum, R. C.</au><au>Chen, C.-S.</au><au>Chidiac, T.</au><au>Schwarzenberger, P. O.</au><au>Thant, M.</au><au>Versola, M.</au><au>Lane, S. R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2005-01</date><risdate>2005</risdate><volume>16</volume><issue>1</issue><spage>97</spage><epage>101</epage><pages>97-101</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: The purpose of this study was to compare quality of life and overall toxicity in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine–gemcitabine (VG) or carboplatin–paclitaxel (Taxol) (CP). Patients and methods: A total of 165 previously untreated patients were randomized to the two regimens. Quality of life was assessed by the Lung Cancer Symptom Scale (LCSS). Overall toxicity and secondary efficacy end points were evaluated by standard WHO criteria. Results: There was no significant difference in overall quality of life between the two treatments. Neutropenia, thrombocytopenia, peripheral neuropathy, and alopecia, were more common in the CP arm, whereas constipation was more frequent in the VG arm. Response rates were 14.6% in the VG arm and 16.9% in the CP arm. Median survival times were 7.8 and 8.6 months, and 1 year survival rates were 38.4% and 31.9%, respectively. Conclusions: Patients treated with VG experienced lower toxicity, but overall quality of life was similar in both arms. Efficacy seemed comparable between VG and CP. Our study shows that VG is a viable alternative to platinum-based chemotherapy in patients with advanced NSCLC.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>15598945</pmid><doi>10.1093/annonc/mdi009</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2005-01, Vol.16 (1), p.97-101 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21296751 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult advanced non-small-cell lung cancer Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carboplatin - administration & dosage carboplatin–paclitaxel Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Female Humans Infusions, Intravenous Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medical sciences Middle Aged Paclitaxel - administration & dosage Pharmacology. Drug treatments Pneumology Quality of Life Survival Analysis Treatment Outcome Tumors of the respiratory system and mediastinum Vinblastine - administration & dosage Vinblastine - analogs & derivatives Vinorelbine vinorelbine–gemcitabine |
| title | Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T00%3A48%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20randomized%20trial%20of%20vinorelbine%20and%20gemcitabine%20versus%20carboplatin%20and%20paclitaxel%20in%20advanced%20non-small-cell%20lung%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Lilenbaum,%20R.%20C.&rft.date=2005-01&rft.volume=16&rft.issue=1&rft.spage=97&rft.epage=101&rft.pages=97-101&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdi009&rft_dat=%3Cproquest_cross%3E21296751%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21296751&rft_id=info:pmid/15598945&rfr_iscdi=true |